Pharmaceutical Executive January 11, 2022
Progress in 2022 will require nimble action across several fronts.
In the coming months, public health officials and biopharmaceutical companies will need to address the ongoing effects of COVID-19, while continuing to develop and produce vital new vaccines and therapies. FDA is relying on swift reauthorization of industry-paid user fee programs to maintain smooth operations, as well as Congressional action on policies affecting the agency and biomedical R&D. These imperatives, however, may be sidelined by mid-term elections in November 2022, where the pandemic response and access to medicines and healthcare services will be prominent issues. Drug pricing will remain a highly charged topic, as the debate continues over patents and the need for global vaccination efforts to control COVID.
In...
Today's Sponsors
Today's Sponsor